Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. The company is headquartered in Boston, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2014-12-18. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. The company is headquartered in Boston, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2014-12-18. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
